Observationa Study is a Prospective and Multi-institutional Observational Study.

Completed

• Conditions: Erosive Reflux Disease; Heartburn; Acid Regurgitation

• Registration Number: NCT06952855
• Lead Sponsor: Jeil Pharmaceutical Co., Ltd.

Brief Summary

This observational study is a prospective, multi-institutional non intervention study to examine the prescription patterns, corresponding treatment effects and safety in routine clinical practice for patients prescribed for the treatment of gastroesophageal reflux disease.

Detailed Description

The present observational study is designed to check effect and safety for patients who have been prescribed JAQBO for the treatment of erosive gastroesophageal reflux disease.

Study Timeline

• Study Start: 2024-11-01
• Study First Submitted: 2025-03-11
• Primary Completion: 2025-04-23
• Study Completion: 2025-04-23
• Study First Submitted QC: 2025-04-28
• Status Verified: 2025-05
• Study First Posted: 2025-05-01
• Last Update Submitted: 2025-05-11
• Last Update Posted: 2025-05-13

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 5536

Inclusion Criteria

1. An adult over 19 years of age
2. A person who voluntarily provides written informed consent

Exclusion Criteria

1. A pregnant woman or a nursing woman
2. A person who is deemed unsuitable for the subject of the study

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Change in GERD (heartburn, acid regurgitation) score in RDQ	4 weeks	Scale(none / 1day / 2day/ 3-4 day / 5-6 day/ every day)

Trial Locations

Locations (1)

Goodbreath Medical Center; 🇰🇷 Seoul, Gyeonggi-do, Korea, Republic of